Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.8% – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares dropped 3.8% on Monday . The stock traded as low as $20.55 and last traded at $20.52. Approximately 29,466 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 226,296 shares. The stock had previously closed at $21.33.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Guggenheim reaffirmed a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $52.14.

Dianthus Therapeutics Price Performance

The company has a fifty day moving average of $22.54 and a two-hundred day moving average of $24.81. The stock has a market capitalization of $625.24 million, a P/E ratio of -8.55 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. As a group, equities research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Quest Partners LLC boosted its stake in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Dianthus Therapeutics by 142.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after purchasing an additional 97,362 shares during the last quarter. MetLife Investment Management LLC boosted its position in Dianthus Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock valued at $382,000 after purchasing an additional 7,854 shares during the period. Walleye Capital LLC bought a new position in Dianthus Therapeutics during the 3rd quarter worth $821,000. Finally, Braidwell LP increased its position in Dianthus Therapeutics by 34.6% in the third quarter. Braidwell LP now owns 493,687 shares of the company’s stock worth $13,517,000 after buying an additional 126,836 shares during the period. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.